| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.18 | 3e-05 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.16 | 3e-05 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | -0.18 | 3e-05 |
| mRNA | OSI-027 | GDSC1000 | pan-cancer | AAC | 0.16 | 6e-05 |
| mRNA | JW-7-24-1 | GDSC1000 | pan-cancer | AAC | 0.16 | 6e-05 |
| mRNA | VNLG/124 | GDSC1000 | pan-cancer | AAC | 0.17 | 7e-05 |
| mRNA | BRD-K51831558 | CTRPv2 | pan-cancer | AAC | -0.24 | 8e-05 |
| mRNA | linifanib | GDSC1000 | pan-cancer | AAC | 0.18 | 9e-05 |
| mRNA | tubastatin A | GDSC1000 | pan-cancer | AAC | 0.16 | 0.0001 |
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | 0.16 | 0.0001 |